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Abstract: This article introduces discussion on the current Korean bio-
industry, its statistical system, R&D expenditure and policies. We also
present a brief discussion of non-economic and social impacts of the bio-
industry in Korea.  In addition, we attempt to estimate trade-related
competitiveness. The major findings of the report are as follows: the bio-
industry in Korea is made up of mostly dedicated firms based on both
modern and single definition. The firms still have diversified lines of
production using both biotechnology and conventional technologies.
Secondly, biotechnology and bio-industry statistical system is currently
well-organized since MKE and KIET took a full charge of the statistical
system and data collection since 2002, but need to work on keeping
consistency with international system such as OECD suggestion and trade
statistics.
The average growth rate of bio-industry over the last 5 years has been 14.4
per cent, more than three times of annual GDP growth in the same period.
The major force behind the Korean bio-industry is the synergy created by
enthusiastic governmental policy and the entrepreneurship of the research-
oriented firms.
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Introduction
The bioeconomy is a dynamic and unique economic development
opportunity for Korea as the country strategically repositions itself for
global change and competition.  The bioeconomy, as a vehicle for growth
for the next generation after conventional manufacturing driven industry,
reducing climate change emissions and other less desirable impacts  and
increasing productivity for the manufacturing industries, is a right choice
for Korea.  We can enhance its existing agriculture, forestry, manufacturing
and biotechnology sectors with value added opportunities presented in
the emerging and continuing bio-industrial shift.
 Asian Biotechnology and Development Review2
The Korean economy represents an important and growing market
for the use and import of biotechnology products. Further, considerable
investment has been made to develop an indigenous biotechnology
industry. The biotechnology sector in Korea has enjoyed considerable
scientific success and has grown to a substantial size mainly due to
continuous fund from both the government and the private sector. Success
has led to a substantial increase in total sales, employment, private and
public R&D, and international trade in recent years. During the years 2002-
2007, biotechnology sales almost doubled from the equivalent of US $20.4
billion to US $ 40.0 billion, an annual increase of 14 per cent, as of 2007
US dollar-Korean won exchange rate. Employment of full time equivalent
in biotech active firms also has increased from 8,604 (Biotech R&D
employees, 5,030) to 20,236 (Biotech R&D employees, 10,178) with an
annual increasing rate of 18.7 (15.1) per cent during the same period.
The Korean government has also promised to increase public
investment budgets as a type of public R&D, infrastructure, and human
resources by 14.4 per cent per annum over the five-year period between
2002 and 2007. The government is firmly committed to the biotechnology
sector with a recent announcement by the Ministry of Knowledge Economy
(MKE) that US$ 1.35 billion would be invested.  This is in addition to
state-based R&D projects valued at US$ 9.2 billion and raising another
US$ 22 billion through issuing state based bonds to foster the
commercialization of next generation technologies, particularly
biotechnology.  This excludes measures such as establishing world-class
research institutions, such as MOGAM Biotechnology Research Centre and
POSTECH Biotech Centre.
The leading private firm groups also established their biotechnology
firms to pursue the business opportunities. Academic or research institutes’
engagement in the bio research is also increasing. Leading firms include:
LG Life Sciences, which develops new drugs for the global market and has
joint development projects with Parke-Davis & Yamanochi of Japan, and
Regen Biotech, Labfrontier, Crystal Genomics, INbionet, etc.
It is estimated that there are more than 800 biotechnology firms in
Korea. Out of these biotechnology firms in Korea, 32 per cent are
biopharmaceuticals 23 per cent bio foods 14 per cent bio chemicals.
Even though Korea is not a top-tier country in all biotechnology
spheres, the number of relevant professional publications in the industry
is estimated to rank top 12 in the world. There are nearly 10,000 research
and technical personnel working in the industry. This research effort has
3yielded a wide array of biotechnological varieties that have gone through
field trials and have been cleared for environmental release and put into
commercial production.
Korea, along with development of biotechnology industry, has also
put a great deal of efforts to establish a consistent data collecting and
analyzing system. The biotechnology industry statistics had been managed
by Bioindustry Association of Korea (BAK) during 1992 to 2002 as an
informal and non-official statistics. Since 2002 MKE has been running an
annual biotechnology firm survey. This survey is officially conducted on
a voluntary basis and has achieved an overall response rate of almost 100
per cent. The survey has shown a stable and consistent set of annual
statistics of biotechnology industry and its activities. Recently the statistical
system has been modified at a detailed level of disaggregation and puts
more focus on trade statistics.
This article introduces discussion on the current Korean bio-industry,
its statistical system, R&D expenditure and policies. We also present a
brief discussion of non-economic and social impacts of the bio-industry
in Korea.  In addition, we attempt to estimate trade-related competitiveness.
Finally, as concluding remarks, we present some findings and implications
for development of biotechnology industry and further research.
Biotechnology Industry Statistics in Korea
Classification of Bio-industry Statistics in Korea
MKE, former Ministry of Commerce, Industry and Energy, has been
running an annual biotechnology firm survey since 2002. This survey is
conducted on a voluntary basis in a sense that there is no specific penalty
for non-responding firms and it has achieved an overall response rate of
near 100 per cent.1 This survey provides a single definition of biotechnology
and uses the Korean Bio-industry classification system. The Korean bio-
industry system classifies biotechnology firms into eight sectors:
biopharmaceutical, biochemical, biofood, bioenvironmental,
bioelectronics, bioprocess and equipment, bioenergy and bioresource, and
bioassay, bioinformatics and R&D services. The survey focuses on ‘modern’
biotechnology.
The major goal of biotechnology industry statistics is to produce
statistical information for both bio- and non bio-firms, policy makers,
international stakeholders in order to understand current state of bio-
industry in Korea and to enhance the industry for the next generation
growth engine of the Korean economy.
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In building and implementing a statistical classical system, most
important to this end was establishing the scope of bio-industry in Korea.
The definition of bio-industry in the Korean system is “an industry
producing goods and services using biotechnology.”  That is, the scope of
bio-industry is determined by biotechnology itself and changes in
accordance with technological innovation. Therefore, it is necessary to
understand biotechnology as the currently used term and to systematize
its classification to obtain more useful bio-industrial statistics.  This process
is also linked with the relative significance and substitutability stemming
from technological innovation in the knowledge-based economy,
legitimate not only for biotechnology but also for other industries
capitalizing on new technologies.
To capture an efficient and manageable bio-industry classification
system in Korea, the technology classification system was founded, based
on which a survey was conducted on the current status of the bio-industry.
With the analysis on the survey results, the standard classification system
of Korea’s bio-industry was set up to facilitate research on the structure of
the industry.  The technology classification system is useful for analyzing
classification indicators as well as the structure of the bio-industry and
producing practical statistical data.
This kind of research will enable the government, public and private
firms and research institutes to recognize critical issues of the bio-industry
by clarifying the status of the real economy relevant to the biotechnology,
and to facilitate the analysis on the economic impact of biotechnology, as
well as to understand inter-industrial relationships among bio-firms in
the perspective biotechnology innovation.
Establishment of the Biotechnology Classification System
The statistics on the Korean bio-industry classified a firm’s application
field according to the broad criteria of the Korean Bio-industry
Classification. There are differences between OECD and the Korea
classification in biotechnology applications or bio-industry.
Bio-industry is defined as “products and processes produced with
biotechnology” and the technologies currently used in the domestic bio-
industry were grouped according to the biotechnology classification
system.  Based on the biotechnology classification system, key technologies
that were primarily used in relevant industrial sectors were screened. The
most important principle in establishing the biotechnology classification
system was the suitability to the purpose of developing a system. Therefore,
5the scope and divisions of biotechnologies were established in order to
better reflect the status of the domestic bio-industry.
Technologies used primarily in the bio-industry were the subject of
the survey but those forecast to be used in the bio-industry in the near
future and expected to have considerable spillover effect were also included
to allow flexibility to the survey. The classification consists of three groups
of Category I, as shown in Table 1.
The level of technologies in Category I could differ. Despite the
difference, however, they were placed in Category I if their impact on the
bio-industry was equally substantial.
The technology classification system was established with the
participation of experts in firms and industries. The classification system
of biotechnology consists of three categories: Category I includes the
Chapters A - M at one-digit level, which comprises 13 items as shown in
Table 1. Category II includes the sub-sectors of Chapters A-M, A1 - M0, at
two-digit level - 68 items. Category III , not in the paper, is more refined
than Category II comprising 319 items.
Table 1: Structure of the Biotechnology Classification System in
Korea
Value Chains Purpose of the Key Biotechnologies
Technologies (Category I)
A. Genetic engineering
R&D Biological Material B. Protein engineering
and Cell C. Other macromolecular engineering
D. Cell and tissue engineering
Bioinfornation E. Systems biology and
application analysis   and bioinformatics
F. Metabolic engineering
Production and Production G. Bioprocess
Applications
Biosecurity and H. Bioresource production and
sustainable utilization
development I. Envionmental and bioenergy
Fusion J. Nanobiotechnology
K. Bioelectronics
Evaluation Safety and efficiency L. Biosafety and bioefficiency
Others M. Other biotechnology
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Korea’s Bio-Industry Classification System and Its Statistical
Significance
Korea’s statistics on its bio-industry have been published by BAK since
1992. However, KIET (Korea Institute for Industrial Economics and
Technology) and MKE took a full charge of data collection, criteria or
guidelines regarding the statistics since 2002.  Moreover, questionnaires
were used in the survey to complement the results of the existing surveys.
Based on the results of this survey, the classification system of the domestic
bio-industry was re-established to obtain statistical data facilitating the
overall analysis of the bio-industry and economy.  Korea is following OECD
definition of bio-forms which may be summarized as below:
• Firms that utilized biotechnology as a key technology in the R&D stage
but used other technology to manufacture products;
• Firms that directly used biotechnology in the manufacturing,
production and service (R&D included) processes;
• Firms that used raw materials which was made with biotechnology
but produced their products using technology other than
biotechnology;
• Firms that produced machines, equipment or plants to be used in the
R&D or production process where biotechnology is involved; and
• Firms that purchased and resold the abovementioned products or acted
as sales agents on contract terms
Bio-firms are basically classified in accordance with their industrial
activities. Industrial activity is defined that any economic activity
progressively pursued by economic players that produce, sell or provide
goods or services. The statistical units used for the bio-industry are firms.
When a firm carries out diverse bio-related activities, the business line of
that firm is classified as that of its activity with the highest sales record.
Firms that concentrated their key products regardless of sales records are
studied separately.
When a firm with manufacturing facilities produces and sells a
specific product on orders from another firm or on contract terms, it is
classified by that product.  When a firm does not directly manufacture a
specific product but commissions another firm for production and takes
over the final product for sales, it is classified by the final product if the
following four conditions are met:
• a firm directly plans a product (concept, design, samples, etc);
• it buys raw materials with its own account and provides them to the
contractor;
7• it manufactures the relevant products in its own name; and
• it takes over the products and sells them directly in the market.
The Korean statistical system is, in principle, decentralized in that each
agency has the responsibilities to collect its statistics relating to its particular
field.  Hence bio-industry statistics is also managed and operated under
the authority with cooperation of separate ministries, with field work of
KIET and BAK.  With the aim of improving the comparability and
consistency of statistics, the authority standardizes bio-statistical terms
and classifications periodically.  These definitions and modifications in
classifying are linked to the Korean Standard Industrial Classification and
the Standard Korean Trade Classification, where biotechnology and bio-
industry statistics are linked in. Trade statistics in bio-goods and services
follow the same broad structure of ISIC Rev 4 (draft version) and selectively
choose detailed modifications.
Table 2: Korean Bio-industry Classification
1. Bio-Pharmaceuticals Industrial activities to produce pharmaceuticals or medical
supplies that are used for the diagnostics, prevention, and
treatment of human or animal diseases utilizing
biotechnology at the stage of research, development, or
manufacture (exceptions: medical devices and medical
diagnostic devices).
1010 Antibiotics
1020 Anticancer medications
1030 Vaccines
1040 Hormones
1050 Immunotherapeutics
1060 Hemotherapeutics
1070 Growth factors
1080 New therapeutics (ex. gene therapeutics, cell therapy,
cloned organs, etc.)
1090 Diagnostic kits
1100 Animal medications
1000 Other biopharmaceuticals
2. Biochemicals Industrial activities to produce chemicals or substitutes by
means of extraction and purification from organisms or
biotechnological process (Goods for medical application
other than polymeric materials are excluded)
2010 Biopolymers
2020 Industrial enzymes and reagents
2030 Enzymes and reagents for research
2040 Biocosmetics and home & personal care chemicals
2050 Biological agrochemicals and fertilizers
2000 Other biochemicals
3. Bio-Foods Drinks, foods, and feeds that humans or animals can uptake,
extracted from living organisms or biotechnological means
are applied at the stage of R&D, manufacture, or production.
Table 2 continued
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Edible or inedible animal and plant fats are included.
(Products for medical applications are excluded).
3010 Functional health foods
3020 Amino acids
3030 Food additives
3040 Fermented foods
3050 Feed additives
3000 Other biofoods
4. Bio-Environmental Industrial activities to provide goods, systems,
   Industry pollution assessments, and structures for cleaning, restoring,
and protecting environment using biotechnology
4010 Microbial treatment agents
4020 Microbe-immobilized materials and equipments
4030 Bioenvironmental agents and systems
4040 Measuring apparatus for environmental pollution
(service for pollution assessment)
4000 Other bioenvironmental productions and services
5. Bio-Electronics Manufacture of medical- or non-medical devices and
apparatus making use of bio-informatics, biotechnology,
nanotechnology, and electronic technology
5010 DNA chips
5020 Protein chips
5030 Cell chips
5040 Biosensors
5050 BioMEMS
5000 Other bioelectronics
6. Bio-Process and Apparatus and plants that utilize living organisms, materials
    Equipment derived from living organisms, or biotechnology for R&D,
manufacture, or production process. Instruments and
apparatus that are used for research and experiment.
6010 Bioreactors
6020 Biomedical and diagnostic apparatuses
6030 Bioprocess and analysis equipments
6040 Plant and process design
6000 Other bioprocesses and equipments
7. Bio-Energy and Industrial activities utilizing organisms or biotechnological
    Bio-Resources processes for obtaining energy sources. Investigation of
organisms having novel functions, creation of organisms by
breeding and genetic transformation, cultivation, or farming
7010 Biofuel
7020 Artificial seeds and seedlings
7030 Experimental animals
7040 Transgenic animals and plants
7000 Other bioenergy and bioresources
8.  Bio-Assays, Bio-Assays, Informatics Service
     Informatics Service 8010 Bioinformatics services
8020 Gene analysis services
8030 Protein analysis services
8040 R&D services(ex. drug development services, etc.)
8050 Biosafety and efficacy evaluation services
8060 Diagnosis and preservation services
8000 Other bioassays, bioinformatics services
Table 2 continued
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Brief History of the Korean Bio-industry
Since the early 1980s, the Korean bio-industry began to introduce and
develop new biotechnology products for industrial purpose.  In 1983, the
Korean government enacted Biotechnology Promotion Law to foster young
bio-firms.  The government, mainly Ministry of Education and Ministry of
Science and Technology, helped to establish biotechnology departments
and research institutes in Universities from the year 1984. As a public research
institute, Korea Research Institute of Bioscience & Biotechnology (KRIBB)
was established in 1985, introducing GEC (Genetic Engineering Center).
From the early 1990s, the Korean bio-industry began to produce goods
and services in a large scale from private firms.  In 1991, the Bio-industry
Association of Korea (BAK) was established and 50 bio-industrial companies
signed to become members of the new organization. Since then, BAK has
been promoting various enterprises to facilitate growth and development
of the bio-industry. The Ministry of Science and Technology formally
launched Biotech 2000 Program in 1994, speeding up the government-
driven biotechnology policies.
Table 3: History of Korean Bioindustry
1980-1989: Technology Development Stage
• Introduction & Development of New Biotechnology
• Enactment of Biotechnology Promotion Law, 1983
• Establishment of Biotechnology Departments & Research Institutes in
Universities, 1984
• Establishment of the Korea Research Institute of Bioscience & Biotechnology of
(KRIBB), 1985
1990-1999: Product Manufacturing Stage
• Establishment of Bioindustry Association of Korea (BAK), 1991
• Formalizing of Biotech 2000 Programme (MOST), 1994
• Proclaim of Bioindustry Vision 2000 (MOCIE), 1994
• Development of Bioprocess Technology & Launching of Bio-products
2000-Current: Bioindustry Introduction Stage
• Establishment of Korean Bioindustry Development Strategy, 2000
- Key National Strategic Industry·
• Inauguration of National Bioindustry Action Plan
• Productivity Improvement of Generic Products, Development of New & Modified
Bio-products
• Investment Increase in Public and Private Sector
 Since the year 2000, coupled with strong government support, the
biotechnology firms in Korea began to garner competitive edge in some
bio-products and services.  The Korean government put a strong effort to
Biotechnology Industry, Statistics and Policies in Korea
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help the industry by entitling the National Strategic Industry and
inaugurating National Bio-industry Action Plan.  In the meanwhile, the
bio-industry has shown a substantial productivity improvement especially
in generic products and development of new and modified bio-products.
We also witnessed a great deal of increase in public and private sector.
The leading private company groups also established their biotechnology
companies to pursue the business opportunities.  Academic or research
institutes’ engagement in the bio research became more active.
The historical analysis of the Korean bio-industry is consistent with
following articles. Artuso (2002) classified Korea, Taiwan and Singapore
by the following common features; (a) political support, (b) government-
led funding opportunities for R&D to commercialize inventions and
applications, (c) collaboration among federal and/or local governments,
the public, universities, and the private sector, and (d) financial and
business support for new biotechnology firms, including venture capital
financing and establishment of national centers.  The report from Rand
(2006) also evaluated Korea as the one of the economically and scientifically
advanced countries, possessing the capacity to acquire all the 16 significant
technologies including biotechnology in the year of 2020.
According to the historical data on the bio-industry in Korea,
obtained from the annual bio-firms survey, total sales of the Korean bio-
industry, combining domestic sales and exports, has been growing rapidly.
The CAGR during the last 5 years is around 14.4 per cent.  The major
driving force behind the Korean bio-industry seems to be the synergy effect
between enthusiastic governmental policies and the entrepreneurship of
research-oriented firms.
Table 4: Total Sales of the Korean Bio-industry (2007 millions of US$)
Year 2002 2003 2004 2005 2006 2007 CAGR)
(02-07)
Biopharmaceuticals 691 925 1,047 1,200 1,313 1,814 21.3
Biochemicals 122 108 154 199 218 252 15.7
Biofoods 957 989 1,137 1,233 1,463 1,416 8.2
Bioenvironmental 105 99 121 155 175 216 15.6
Bioelectronics 9 8 17 20 28 62 46.2
Bioprocesses and equipment 74 46 49 61 80 91 4.2
Bioenergy and bioresources 46 14 10 17 17 27 -9.8
Bioassay, bioinformatics, etc. 34 47 69 98 105 118 28.0
Total 2,038 2,237 2,604 2,983 3,400 3,997 14.4
In 2007, biopharmaceuticals and biofoods together dominated
production by biotechnology firms, accounting for 80.8 per cent and
followed far behind by biochemicals (6.3 per cent).
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R&D Trend of the Korean Bio-industry
The high growth of the biotechnology industry stems from the
government’s intensive investment in R&D and social infrastructure. By
doing this, the government encouraged firms to invest actively in the
biotechnology industry.  Figure 1 shows investment expenditures by the
government and private firms in the biotechnology industry.  As shown
in Figure 1, the amount of government’s investment increased rapidly at
an average of 27.5 per cent per year, greater than that by firms’ investment
with 17.5 per cent.  Furthermore, the government expenditure was nearly
the same as the firms’ investment.  From 2001 to 2004, in particular, public
investments exceeded private investment in biotechnology.  Here, doubts
can be raised as to whether government’s investment may cause a
crowding-out effect on firms’ investment.
As shown in Figure 2, there is a sharper fluctuation in the annual
growth rates of government investment.  We can compare the change in
direction of the growth rate in the investment of the two parties.  For
example, from 1999 to 2000, the growth rate of government investment
changed from 44 per cent to 53 per cent, which indicates a plus sign change.
Note that there are only the years, 2000 and 2004~2006 when the direction
of the two growth rates are reverse.  We may refer that government
investment could have a reverse impact on the growth rate change in the
private investments for the years. In this case, government investment
might crowd out private investment by decreasing the growth rate in firms’
investment.  This can be explained in that, from 2004 to 2006, government
investment substituted for firms by investing in areas where firms could
play the same roles.
Figure 1: Public and Private Investment in the Korean
Bioindustry
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Table 5 shows total public R&D expenditures by periods and major
government providers. MEST, which is a new combined ministry of
education, science, and technology, is the largest public fund provider
during the period 1994~2007, accounting for 44.6 per cent, followed by
MKE, .18.9 per cent during the same period.  In recent years, especially in
2007, the share of MEST became relatively lower with more emphasis on
commercialization of fundamental biotechnologies.  Table 6 shows
distribution of pure public R&D by biotechnology divisions.  Life science
accounted for the largest share for both years, followed by health sector.
Table 5: Public R&D Expenditures and Providers (2007 millions of US$)
R&D fund provider 1994-97 1998-’01 2002-06 2007 1994-’07
Ministry of Knowledge 18 140 707 193 1058
Economy(MKE)
Ministry of Education, Science and 253 564 1335 352 2503
Technology (MEST)
Ministry of Food, Agriculture, 86 111 433 133 764
Forestry and Fisheries (MAF)
Ministry of Environment (ME) 10 21 111 140 282
Ministry of Health, Welfare 48 95 654 29 827
and Family Affairs (MW)
Public research institutes 0 0 76 100 177
Sum 415 932 3317 946 5610
Note: Public R&D includes pure research activities, infrastructure, human resource
development.
Source: Biotech Policy Research Center, 2008; KIET, Annual Biotechnology Industry Survey,
2008.
Figure 2: Growth Rates of Public and Private Investment
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In terms of R&D investment, Korea could not invest significant
amounts of capital directly because the market is not yet mature and thus,
revenues are relatively so small.  Due to the relatively short history in
biotechnology, the industry may not produce fair amount of rate of return
in R&D. The problem of low rate of return from R&D is regarded to stem
from less active commercialization from own R&D and technological
innovation in biotechnology industry.
Table 6: Distribution of Pure Public R&D Expenditures (2007
millions of US$)
Life science Health Agri. Food Ind. Process Bio-fusion Sum
2007 274 178 101 104 91 748
2008 314 221 107 100 94 836
change, 14.9 24.1 5.7 4.2 2.9 11.7
per cent
Note: Pure public R&D includes only research activities.
Source: Biotech Policy Research Center, 2008; KIET, Annual Biotechnology Industry Survey, 2008.
So far, 12 new drugs including a new bio-drug have been licensed
from the Korea FDA.  Among them, 7 drugs achieved sales of over 10
billion won (around US$8 million) annually.  Even though considering
the relatively smaller size of market than US, the results are not good
performances, compared to the 23 new bio-drugs with sales of over US$1
billion annually in the United States.  In the years, 2003-2005, Korean
firms obtained FDA 2, 4, and 1 license(s) in the United States in the market
launching, phase II clinic, and I clinic, respectively.   These figures also
reflect the low level of commercialization of developing biotechnologies,
compared to new bio-drugs approved ranging from 20 to 40 by the FDA
during the years 1999 to 2005, summing up to 230.  In the pharmaceutical
industry, compared with 602 trillion won of the world market, Korea’s
market is only 7.8 trillion won in size, accounting for 1.3 per cent.  While
the largest amount of the sales by firms was 46 trillion won worldwide,
the highest sales reached was 0.5 trillion won in the Korean market, or 1.1
per cent of the world market.
While the proportion of the research expenditure to sales is 15-20
per cent in North America and Europe and 12 per cent in Japan, Korea
have reached only at 4-8 per cent, resulting from a net profit ratio of less
than 5 per cent.  While the number of researchers per firm is 500-15,000
persons in North America and Europe and 100-2,000 persons in Japan,
the researchers per firm in Korea ranges only 20-300 persons in Korea.
Biotechnology Industry, Statistics and Policies in Korea
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Moreover, the research experience on new drug development is relatively
short, around 20 years in Korea, compared with 60 years in North America,
100 years in Europe, and 35 years in Japan.
The biotechnology industry in Korea is in the early stages of
development in carrying out R&D investment.  In most areas R&D and
marketing capabilities including Korea has some weaknesses, compared
with advanced countries, especially the United States.  In order to improve
R&D capabilities, a national R&D system should be revised to provide
incentives for cooperation with outside networks.  According to the needs
of host R&D actors, the evaluation systems used by other R&D actors should
be differentiated from those in projects carried out independently.  From
this point of view, it is important for universities and public institutes to
contribute to the industry in two ways:  First, they need to focus their
research in bio sciences and relevant technologies and, secondly, support
commercialization by providing applied technologies under a different
system for evaluating R&D outputs.
Firms, Employment, Papers, and Patents of the Korean Bio-
industry
The total manpower has increased in the field of biotechnology quite
considerable in recent years.
Number of graduates majoring in the biotechnology and bio-
engineering, including bachelor, master, and Ph.D., increased consistently
reaching 29,256 graduates with annual increasing rate of 2.4 per cent from
2004 to 2007. In 2007, Bachelor degree holders accounted for 66.5 per
cent of total; masters, 24.1 per cent; Ph.D., 9.4 per cent (Figure 3).
Figure 3: Graduated Students from Biotechnology
and Bio-engineering
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The total number of employment also increased rapidly.  The
biotechnology manufacturing facilities tend to locate in rural areas, near
the source of their raw materials and biotechnology services and research
centers tend to locate in metropolitan or near the large cities.  The jobs
associated with the bio-industry offer above average wages.  Further,
according to inter-industrial analysis, only about small portion of the jobs
that can be attributed to a bio-industry facility is created directly at the
plant.  Many are created when the plant buys supplies and raw materials.
From 1998 to 2007, total employment increased by 22.1 per cent
annually; for the periods of 2002 to 2007, by 9.8 per cent (Figure 4).
Researchers increased by 19.9 per cent (8.0 per cent for 2002 to 2007) in
the same period; manufacturing and service workers at site, by 24.8 per
cent (12.0 per cent for 2002 to 2007).
In 2007, there 834 firms were active in biotechnology in Korea.  The
largest share of employees worked in the biopharmaceutical sector (40.5
per cent), followed by the biofood sector (24.0 per cent) and biochemical
sector (11.7 per cent).  Over half of the employees had R&D-related duties
(50.3 per cent or 10,178 employees), as shown in Table 7. Average number
of employment per firm is 24, ranging from 31 (biopharmaceutical sector)
to 14 (bioelectronics).
Thanks to such increase in the human and physical investment, the
scientific and industrial outcomes, including professional papers and
publications, have risen continuously. The number of SCIE study increased
to 4,909 in 2007 by 1.7 times compared to 2002 (2,879) in Phase III, that
is 11 per cent per annum (Figure 5).
Figure 4: Employment in Biotechnology Industry (Unit Persons)
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Table 7: Total Sales of the Korean Bio-industry (2007 millions of US$)
Sub-industry           Firms Employment
number share number average share,
per cent
Biopharmaceutical Ind. 266 31.9 8,196 31 40.5
Biochemical Ind. 117 14.0 2,377 20 11.7
Biofood Ind. 188 22.5 4,864 26 24.0
Bioenvironmental Ind. 111 13.3 1,775 16 8.8
Bioelectronics Ind. 21 2.5 304 14 1.5
Bioprocess and equipment Ind. 62 7.4 1,238 20 6.1
Bioenergy and bioresource Ind. 25 3.0 618 25 3.1
Bioassay, bioinformatics and R&D 44 5.3 864 20 4.3
Sum 834 100.0 20,236 24 100.0
Source: KIET, Annual Biotechnology Industry Survey, 2008.
The Korean firms have established their edge in product and process
technologies through their focus on R&D. These R&D efforts and human
resources, in turn have the potential to provide competitive advantage
resulting in improved firm performance. It is the accumulation of
knowledge and technological strength resulting from R&D efforts that
determines the performance of the firm. Korea focuses on the intermediate
results of R&D and human resource development efforts. These can be
measured in terms of the number and the quality of patents granted to
firms.
Figure 5: Professional Papers of Biotechnology
and Bio-engineering
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For the initial scratch of the competitiveness review, the number of
patents both in overseas and in domestic area, has increased continuously,
with slight decline in 2007, as shown in Figure 6. Out of total patent
application acquired from overseas, 596 items, the US patents accounted
for 18 per cent.
To better understand the economic inversion and the relative
contribution of intangible and tangible assets to innovation, we applied
economy-wide and biotechnology industry-specific statistical indicators
measuring intangible assets. One embodiment of innovation is patents as
explained above, but innovation cannot be measured by a simple patent
count. Stated directly, patents are the single most fundamental measure
of innovation, but only the overall competitiveness can be measured by
including effectiveness of the patents
 Technology Specialization (TS), as an index for measuring the
competitiveness of the Korea biotechnology and industry, is determined
by multiplying a country’s number of patents during the period by the
current PII (patent impact index). The current patent impact index is a
measure of how important a country’s patents are based and how often
they are cited in other patents, which shows how frequently they are used
as the foundation for other inventions.  A PII ratio of 1.0 is defined that
the country’s patents were cited as often as the overall average during
certain periods. Table 7 shows patents in US, PPI, TS, and ranks for the
relevant periods.  The TS was ranked 17th in 1998 to 2001.  The ranking
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Figure 6: Trend of Patents of the Korean Biotechnology
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has improved to 15th in 2002~2005 and 13th in 2006~2007, reflecting a
gradual gain of competitiveness in the biotechnology.
Table 8: Biotechnology Patents and Competitiveness
Patents Patent Impact Index (PII)
98-01 02-05 06-07 98-01 02-05 06-07
178 207 170 0.440 0.637 0.645
Technology Specialization (TS)
98-01 02-05 06-07
TS value Rank TS value Rank TS value Rank
78 17 131 15 109 13
Note: Based on USPS data.
Source: Biotech Policy Research Center, 2008; Korean Patent Office, 2008.
Bio-industry Trade in Korea
The growth in the use of biotechnology in the processes producing of a
variety of goods and services has led to questions whether biotechnology-
related activity could somehow be reflected in standard statistics
classification in most countries as well as OECD and UN ISIC system.  In
general, industry statistics is classified based on commodities. Therefore,
the technology-input goods and services was thought to be difficult to
distinguish from those produced without such input.  However, with the
continuous efforts of OECD and participating countries, the particular
case of biotechnology and bio-industry has been quite successfully
compiled in conventional statistics system, as has done in Korea
Biotechnology and bio-industry statistics in Korea has been compiled
as a distinct activity based on both rules of general statistical system in
Korea, such as KSIC (Korea Standard Industry Classification) 8th rev. and
SKTC (Standard Korean Trade Classification), a consistent trade statistics
of SITC. Trade statistics of bio-industry in Korea is also complied as the
above rules.
For a simpler comparison, that is either export- or import-oriented
for a bio-industry product or service, STSI (Simple Trade Specialization
Index) is estimated.  For more precise analysis of inter- or intra-industry
specialization review, Grubel-Lloyd Index (GL) calculates if the trade
between two countries is of an intra-industry or inter-industry nature,
that is if countries or regions exchange the same kind of products or not
(Figure 7). When the index is equal to 1, the bilateral exchange reveals an
intra-industry nature; if the index is 0, the pattern of trade is of an inter-
industry nature.
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Table 9: Exports and Imports of the Korean Bio-industry (2007
millions of US$)
Import
1998 2002 2007 98-07 02-07
per cent per cent
Biopharmaceutical Ind. 84 219 853 29 31
Biochemical Ind. 22 62 92 17 8
Biofood Ind. 4 7 13 14 14
Bioenvironmental Ind. 2 2 6 11 26
Bioelectronics Ind. 0 6 1 14 -31
Bioprocess and equipment Ind. 55 188 130 10 -7
Bioenergy and bioresource Ind. 16 0 4 -15 125
Bioassay, bioinformatics and R&D 0 0 0 -23 42
Total 183 484 1,099 22 18
Export
1998 2002 2007 98-07 02-07
per cent per cent
Biopharmaceutical Ind. 200 190 452 9 19
Biochemical Ind. 242 18 49 -16 22
Biofood Ind. 62 752 1,004 36 6
Bioenvironmental Ind. 0 9 9 76 -1
Bioelectronics Ind. 0 9 38 304 32
Bioprocess and equipment Ind. 3 11 22 27 15
Bioenergy and bioresource Ind. 12 1 1 -29 -12
Bioassay, bioinformatics and R&D 0 3 10 26 25
Total 518 993 1,584 13 10
Source: KIET, Annual Biotechnology Industry Survey, 2008.
Figure 7: TSI and Glubel-Lloyd Index in the Bioindustry in Korea
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Product differentiation with scale economies well explains the
exchange of varieties or intra-industry. (GL closes to 1)  For the survey
periods, sub sectors of bio-industry show quite consistent in trade
specialization; biopharmaceutical, biochemical, bioprocess and equipment
are net importers, and biofood and bioelectronics are net exporters. GL
index for overall biotechnology industry becomes higher, reflecting that
the industry is getting more specialized as sub-sectoral level within the
industry. Korea has shown a relatively higher specialization in biochemical
sector and bio-environmental industry.
For better managing bio-industry trade statistics and policy planning,
the government is putting more efforts on regular review for better linking
KSIC (ISIC) and SKTC (SITC and HS).  The statistical authority and stake
holder institutes are closely working together to review better adjustment
of list-based biotechnology product and service regarding trade.  Recently,
group of participating expertise are carefully reviewing SITC (Standard
International Trade Classification) and BTN (Brussels Tariff Nomenclature)
for maintaining consistent biotechnology trade statistics
It will take some times to include modern biotechnology activities
and trade since the conventional industry activities which are based on
commodities and services, not on technology itself.  Secondly, the biotech
firms are still found in many industrial sector in Korea and the firms are
engaged in biotechnology as part of its main activity.  Therefore, it is not
easy task to sort out dedicated bio-tech trade from other.
The statistical analysis such as trade specialization and inter- and/or
intra-industry index as shown above indicates the consistency and
potential improvement of data collection and trade policy in biotechnology
industry.  Since the suggested biotechnology classification such as ISIC 4
are widely ranged even in level of classes, experimental analysis of
biotechnology trade classification helps to check consistency of bio-data
scope and estimation.
Bio-industry activities from cross-border supply, consumption abroad,
commercial presence, and presence of natural persons are increasing.
Therefore, we are trying to carefully define domestically and to harmonize
with international standards.  Moreover, for the commercial presence of
bio-industry activities, the Korean government attempts to establish
consistent statistics compiling system and regulatory policies regarding
in-bound and out-bound FDI of biotechnology activities.
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Bio-industry Regulations and Policies in Korea
The Korean government has been playing a key role to enhancing solid
fundamentals for developing biotechnology industry since 1980s.  In 1989,
under the supervision of the Advisory Board of Development of High
Technology Industry, the Korea Institute for Industrial Economics and
Trade established a subcommittee of bio-industry and proposed a
bioindustrial development project to understand the concept of the field
of bio-industry, and established a vision for bio-industry and a development
project for 2000 in 1994.  In the late 1990s, the Korean government
established a new phase of vision for the field of bio-industry thereby
raising investment efficiency and facilitating the development of industrial
structure. The Ministry of Commerce, Industry and Energy, with of
cooperation of the Korea Institute for Industrial Economics and Trade,
proposed an overall picture of the field of bio-industry.
Figure 8: National Science & Technology Administration System
on Biotechnology
Ministry of Knowledge Ministry of National Defense
Economy (MKE) • Agency for Defense Development
• Agency for Technology and standards • Military Manpower Administration
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• Industrial Property Office
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• National Institute of Health Research
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& Transportation • Rural Development Administration
• National Railroad Administration - Agricultural Research Institute
• Forestry Service
- Forestry Research Institute
Ministry of Education, Science Ministry of Finance and Economy
and Technology (MEST)
• National Universities and Colleges • National Tax Service
• Basic and Leading-edge Technologies • Customs Service
• Promotion of Biotechnology- • Public Procurement Service
supporting Systems • National Statistical Office
• Education
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Since 2000, though some of R&D and commercialization are increasingly
transferred to private sectors, the government still supports major public
policies including developing fundamental biotechnologies, managing
research institutes, building bio-infrastructures, and education.  The
Ministry of Knowledge Economy (MKE, http://english.mke.go.kr/) and the
Ministry of Education, Science and Technology (MEST, http://
english.mest.go.kr/) are two major ministries.  MKE is basically taking
charge of applied biotechnologies and industrialization, and development
of bio-related renewable energy.  MEST plays a key role in basic and leading-
edge technologies, promotion of biotechnology-supporting systems,
education and human resource development.  The ministry also supports
basic research on life science and other relevant fields.
The Ministry of Health, Welfare and Family Affairs (MW) is the official
body responsible for management and making policies for developing
new biopharmaceuticals (http://english.mw.go.kr/front_eng/main.jsp).
The ministry is also in charge of clinical trials and safety-related regulations
regarding biotechnology.  The Ministry of Food, Agriculture, Forestry and
Fisheries (MAF, http://english.mifaff.go.kr/main.tdf)’s major tasks include
breeding animals, plants , and new food additives, conservation of marine
resources, and gene analysis of the marine species.  The Ministry of
Environment (ME, http://english.me.go.kr/) is the authority for
preservation and use of biodiversity, development of waste treatment
technology
In addition to their significance for economic growth and policy
planning, the biotechnology and the bio-industry have a broader impact
as they dramatically affect human health and welfare and promote the
innovation in the other technologies and industries through the
convergence and linkage processes.  The ethical, legal, and social
implications (ELSI) of biotechnology are important for the reasons
described below.
First, biotechnology and bio-industry influence health-care strategies
and behaviours, eventually affecting health-care related factors.  Secondly,
the impact of intellectual property in accessing and using of biotechnology
is significant.  Accordingly, national competitiveness differences are derived
from intellectual property of biotechnologies and bio-industries, which
are closely related to the quality of life.  Also, cutting edge biotechnology
R&D and applications that specifically involve human and participation
need acceptance of society. Biotechnology and the bio-industry co-evolve
with the society. So how different individuals, cultures and religious
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traditions respond to this biotechnology has to be understood.  Finally,
biotechnology-related-environmental issues such as bio-safety and bio-
security have an impact on development and acceptance of biotechnology.
The Korean government has established the required infrastructure
Strong protection for IPR
• Korea is an IP safehold - Regional Head, Leading
Multinational Corporation
The Act on Bioethics & The Act on Cross-border Movement
Biosafety (2004) of Living Modified Organisms (2001)
• To ban human cloning/cross-species • To implement Cartagena Protocol to
experiments the Convention
• To allow research for therapeutic • On Biological Diversity Importation
purpose on frozen eggs left unused and manufacturing of GMOs requires
from fertility treatment & somatic safety and government authorization
cells nuclear transfers
International
Agreement
Bioethics
Bio-safety
IPR
Protection
Figure 9: Establishing of Legal and Institutional Frameworks
and introduced laws related to bio-safety, bio-security, and bioethics, in
order to facilitate compliance of biotechnology and the bio-industry.
However, there is still need for more infrastructure and societal “software”
is also required for the ELSI of biotechnology and bio-industry. In IPR, the
government has a very strong stance for protection of IPR.
Korea is an IP a safe-hold country and plays the role of regional head,
and is a leading figure in the area, especially taking into account increasing
multinational corporations.
In bioethics and bio-safety, the government implemented the Act
on Bioethics & Biosafety in 2004. The act bans human cloning/cross-species
experiments. However, it allows research on frozen eggs left unused from
fertility treatment and somatic cells for therapeutic purpose.  In accordance
with international agreement regarding biosafety and ethics, Korea enacted
the Act on Cross-border Movement of Living Modified Organisms in 2001.
The act is for implementing Cartagena Protocol to the Convention on
Biotechnology Industry, Statistics and Policies in Korea
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Biological Diversity.  In addition, importation and manufacturing of GMOs
requires government authorization and biosafety regulations.
Major Government Strategic Projects under Progress
The Biotechnology Transfer Center helps build smooth system for
transferring technology by the domestic bio-venture companies. They also
facilitate closer interaction between domestic and foreign bio-related
technical firms and thereby activate the technology transaction market
and enlarge the scale of technology market. The Center has various
initiatives which are being summarised as following:
The Bio-Industry Specialized Production Manpower Development
Project is to re-educate the professional production manpower on site
utilizing the infra such as the pre-established equipment and manpower
at the 9 regional Bio Centers throughout the nation, and thereby enhance
the technical power of Bio-Industry and diffuse such atmosphere down to
the local territories. (Promotions Status; 2, 112 persons for site worker
level and 871 persons for preliminary manpower since 2002).
The Bio-medicine/Bio-internal Organ International Standards
Infrastructure Building Project operationalises the research club as the
decision making and policy organization to lead the countermeasure
guideline in supporting the proposal for bio-medicine international
standards. The guidelines are in the draft form but they reflect the urge to
get domestic technology close to the international standards.
The Site Training Project for the Unemployed in Science &
Engineering Field is to provide hands-on experience to unemployed
students majoring in bio engineering. The training is also supplemented
by the courses of theory and further practice in the professional institute
equipped with the test and practice apparatus and give them the chance
to have the practical experience through the site training in bio industry
(Promotion Status: supported 49 job offering companies, 136 job seekers
and 46 companies that wants trainee).
The Small Business Administration Technology Research Association
Project is to organize a consortium among the representative agency
association, several interested companies and universities for carrying out
the research for joint project aiming bio venture enterprises, and thereby
joint development of the primary high-tech technology that cannot be
developed independently through the cooperation on project basis by
the specialized venture enterprises. (Pomotion Status: 17 companies and
7 universities participated for 4 year since 2003).
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The BIT Industry Technology Roadmap programme is to derive the
strategic product and core technology by predicting  the future demand
in industrial field where Bio-Industry BT can be incorporated technically,
and establish the technological plan suggesting the best strategy to
accomplish this target. Distinctively from the existing roadmap it focused
on the development of products and technology to establish the Next -
Generation Growth Engine (a comprehensive roadmap) incorporating the
methods of technology development, manpower demand prospect,
infrastructure set  up and international cooperation inevitably required
to develop the prosperous new products.
Concluding Remarks
As is evident, the foregoing discussion has provided a general review of
biotechnology and the bio-industry structure related policies and future
role of this in the Korean economy.  The major findings of the report thus
far are as follows: the bio-industry in Korea is made up of mostly dedicated
firms based on both modern and single definition. The firms still have, in
some degree, diversified lines of production using both biotechnology
and conventional technologies.  Secondly, biotechnology and bio-industry
statistical system is currently well-organized since MKE and KIET took a
full charge of the statistical system and data collection since 2002, but
there is need to ensure uniformity with international systems, such as
OECD, for comparable policy suggestions and trade statistics.
According to the historical data set on the bio-industry in Korea,
obtained from the annual bio-firm survey, the Korean bio-industry has
been experiencing rapid growth. The CAGR over the last 5 years has been
14.4 per cent, more than three times of annual GDP growth at the same
period.  The major force behind the Korean bio-industry is the synergy
created by the supportive governmental policy and the entrepreneurship
of the research-oriented firms. There are wide variations in value addition
within the bio-industry. In Korea, bio-pharmaceuticals, as a highly
technology-oriented industry, has the highest share of sales, employment
and R&D and are the second highest in exports.  The sector, with stringent
competition and industry diversification depending on development stage,
will play a major role for a while.  However, in future, there is very strong
potential in bio-food and bio-resources in cooperation with Asian countries.
The government must consider a shift in its major policy role from
enhancing overall bio-industry development to more R&D intensive
approach for fundamental technology development and implementation
of efficient regulatory system for IP and biosafety for long term competitive
edge in the wider global context.
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Endnotes
1 The Korean biotechnology industry statistics is implemented to provide relevant
information for enhancing biotechnology industry, planning biotechnology
policies, keeping consistent standardization of biotechnology industry scope and
definition, and finally helping international comparison.The statistical survey is
based on Statistics Act 3, Article 3, Verification No. 11515 as a general statistics
category, and is implemented annually.
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